Feed OSUR
OS

OraSure Technologies, Inc.

OSUR · NASDAQ

$3.69 +2.36% (+$0.08)
1M -3.40%
Market Cap $254.1M
P/E Ratio -
Div. Yield -
ROE 14.73%

Bulios Fair Price

$3.01

18.4% downside

Current Price

$3.69

Undervalued Fair Value Overvalued

According to Bulios Fair Price, OSUR is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
86 /100
Cheap
P/S 2.26x
P/B 0.80x
P/E N/A
Growth
3 /100
Declining
Rev. growth 33.29%
Book val. growth 2.21%
EPS growth N/A
Profitability
16 /100
Weak
Gross margin 41.38%
Net margin 43.70%
FCF margin 42.76%
Quality
4 /100
Poor
ROIC 15.02%
ROE 14.73%
Asset turnover 0.31x
Debt
100 /100
Low
Debt/Equity 0.04x
Current ratio 8.88x
Int. coverage N/A
Stability
32 /100
Unstable
Beta 0.99x
Rev. volatility 30.40%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about OSUR
Online

About the company

OraSure Technologies, Inc. (OSUR) is a company focused on diagnostic solutions and testing in the healthcare sector. With over two decades of history, OraSure Technologies is a leading provider of technologies for non-invasive diagnostics and monitoring of infectious diseases and other health conditions. Their innovative products include rapid tests, genetic analyses, and laboratory diagnostics. The company is also engaged in combating the spread of diseases and supports health prevention and care. OraSure Technologies, Inc. (OSUR) shares could be suitable for investors who want to contribute to the development of advanced diagnostic technologies and the improvement of healthcare.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Carrie Eglinton Manner

Employees

500

Headquarters

Bethlehem

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.